Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19

NCT05886816

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Texas Southwestern Medical Center
Enrollment	112 participants

Key Eligibility Criteria

Inclusion (1)

• Age 18-65 years old Asymptomatic (no symptoms of viral infection) on study entry High risk exposure without use of masks to confirmed case of COVID-19 Members in a household one of which is a confirmed case of COVID-19 Negative baseline SARS-COV-2 diagnostic test

Exclusion (15)

• Women with variations in physiological functions due to hormones that may effect immune function and (transgender, pregnant, breastfeeding)

• Specific significant clinical diseases \[cardiovascular disease (such as coronary artery/vascular disease), heart disease (such as congestive heart failure, cardiomyopathy, atrial fibrillation), lung disease (such as chronic obstructive pulmonary disease, asthma, bronchiectasis, pulmonary fibrosis, pleural effusions), kidney disease (glomerular filtration rate or GFR less than 60 ml/min/1.73 m2), liver disease (such as cirrhosis, hepatitis), major immunosuppression (such as history of transplantation, uncontrolled HIV infection, cancer on active chemotherapy\] based on history. Participants with well controlled HIV (CD4 count \> 500 cells/mm\^3 and HIV viral load \< 50 copies/ml) and people with remote history of cancer not on active treatment will be allowed to participate.

• History of known gastrointestinal disease (such as gastroparesis) that may predispose patients to nausea

• History of auto-immune diseases

• Chronic viral hepatitis

... and 10 more (see full listing online)

Locations (1 total)

University of Texas Southwestern Medical Center, Dallas, Texas, United States